Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 1% – What’s Next?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares were down 1% during trading on Monday. The stock traded as low as $14.11 and last traded at $14.26. Approximately 281,414 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 476,393 shares. The stock had previously closed at $14.41.

Wall Street Analysts Forecast Growth

DRTS has been the subject of a number of recent analyst reports. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Barclays lifted their price target on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Finally, HC Wainwright boosted their price target on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Alpha Tau Medical currently has a consensus rating of “Hold” and an average target price of $15.40.

Alpha Tau Medical Price Performance

The stock has a market capitalization of $1.22 billion, a PE ratio of -12.98 and a beta of 1.22. The stock’s 50 day moving average is $14.50 and its two-hundred day moving average is $11.56. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). On average, equities analysts anticipate that Alpha Tau Medical Ltd. will post -1.05 EPS for the current fiscal year.

Insider Buying and Selling at Alpha Tau Medical

In other news, CFO Raphi Levy sold 17,730 shares of Alpha Tau Medical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total value of $248,220.00. Following the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at $1,262,520. The trade was a 16.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DRTS. Renaissance Technologies LLC purchased a new position in Alpha Tau Medical in the 1st quarter valued at $286,000. Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical during the first quarter worth $132,000. Finally, Everhart Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical during the second quarter worth $126,000. 2.65% of the stock is owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.